Thomas P. O’neil Sells 8,000 Shares of Protagonist Therapeutics Inc (PTGX) Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) CFO Thomas P. O’neil sold 8,000 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $20.00, for a total transaction of $160,000.00. Following the completion of the sale, the chief financial officer now owns 4,000 shares of the company’s stock, valued at approximately $80,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) opened at $19.55 on Friday. Protagonist Therapeutics Inc has a 1-year low of $8.00 and a 1-year high of $22.54.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Monday, November 6th. The company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.40. The business had revenue of $8.78 million during the quarter. equities analysts expect that Protagonist Therapeutics Inc will post -3.66 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of PTGX. Rhumbline Advisers purchased a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $114,000. Wells Fargo & Company MN grew its stake in shares of Protagonist Therapeutics by 60.8% in the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after buying an additional 3,617 shares during the period. Teachers Advisors LLC grew its stake in shares of Protagonist Therapeutics by 71.4% in the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after buying an additional 6,757 shares during the period. Northern Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $188,000. Finally, California State Teachers Retirement System grew its stake in shares of Protagonist Therapeutics by 8.5% in the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares during the period. 39.68% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on PTGX shares. ValuEngine upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BMO Capital Markets increased their price objective on shares of Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. BidaskClub downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $32.67.

TRADEMARK VIOLATION NOTICE: “Thomas P. O’neil Sells 8,000 Shares of Protagonist Therapeutics Inc (PTGX) Stock” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/22/thomas-p-oneil-sells-8000-shares-of-protagonist-therapeutics-inc-ptgx-stock.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

What are top analysts saying about Protagonist Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Protagonist Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit